{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:55:25Z","timestamp":1793228125952,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The practice guideline for outpatient parenteral antimicrobial therapy (OPAT) aims to encourage broader adoption of OPAT into routine clinical practice in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The guideline was developed according to the guideline development framework by the Association of the Scientific Medical Societies (AWMF) in Germany. Literature search was conducted, and expert recommendations were formulated through consensus and published as an AWMF S1 guideline (expert group recommendations with consensus development in an informal process).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>OPAT is a safe and effective alternative to inpatient care for managing selected infectious diseases (ID) entities, which require intravenous antimicrobial therapy (AMT). ID specialists play a critical role in determining the indications for OPAT, the selection of suitable patients and the development of treatment plans. Specialist-led OPAT programs have been shown to enhance treatment efficacy, reduce hospital readmissions, and decrease healthcare costs. A structured, checklist-based approach is used to evaluate infection severity, available therapeutic options, patient comorbidities, and home care conditions. Adherence to antimicrobial stewardship (AMS) principles as well as regular clinical and laboratory monitoring are essential to ensure appropriate antimicrobial use and minimize adverse events, catheter-related complications and the risk of resistance. The selection of adequate vascular access is based on patient-specific factors, characteristics of the indicated antimicrobial and treatment duration, optimizing both safety and patient comfort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>OPAT is a safe, cost-effective alternative to inpatient care, requiring specialists\u2019 ID expertise and AMS. The guideline provides a framework for successful implementation in Germany.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-025-02619-4","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T08:41:03Z","timestamp":1755852063000},"page":"2701-2715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Practice guidelines for outpatient parenteral antimicrobial therapy (OPAT) in Germany"],"prefix":"10.1007","volume":"53","author":[{"given":"Lukas","family":"Tometten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Trost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Achterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Arenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Audebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Bickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Dolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Draenert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Ewering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Friedrichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Hennigs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Isner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Khatamzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lanckohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate Sigrid","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schmiedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil-Robin","family":"Tepasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike","family":"Waldeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Stegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"2619_CR1","doi-asserted-by":"crossref","unstructured":"Mir\u00f3n-Rubio M, Gonz\u00e1lez-Ramallo V, Estrada-Cuxart O, Sanroma-Mendiz\u00e1bal P, Segado-Soriano A, Mujal-Mart\u00ednez A et al. Intravenous antimicrobial therapy in the hospital-at-home setting: data from the Spanish Outpatient Parenteral Antimicrobial Therapy Registry. Future Microbiol. 2016 [cited 2025 Mar 8];11(3):375\u201390. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26974259\/","DOI":"10.2217\/fmb.15.141"},{"key":"2619_CR2","doi-asserted-by":"crossref","unstructured":"Chapman ALN, Patel S, Horner C, Green H, Guleri A, Hedderwick S et al. Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK. JAC Antimicrob Resist. 2019;1(2):dlz026. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34222901\/","DOI":"10.1093\/jacamr\/dlz026"},{"key":"2619_CR3","doi-asserted-by":"crossref","unstructured":"Subedi S, Looke DFM, McDougall DA, Sehu MM, Playford EG. Supervised self-administration of outpatient parenteral antibiotic therapy: a report from a large tertiary hospital in Australia. Int J Infect Dis. 2015 [cited 2025 Mar 8];30:161\u20135. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25603999\/","DOI":"10.1016\/j.ijid.2014.11.021"},{"key":"2619_CR4","doi-asserted-by":"crossref","unstructured":"Emilie C, de Nocker P, Sa\u00efdani N, Gilchrist M, Seaton RA, Patel S et al. Survey of delivery of parenteral antimicrobials in non-inpatient settings across Europe. Int J Antimicrob Agents. 2022;59(4):106559. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35227827\/","DOI":"10.1016\/j.ijantimicag.2022.106559"},{"key":"2619_CR5","doi-asserted-by":"crossref","unstructured":"Britt RS, Pearson JC, LaSalvia MT, Mahoney MV, McCoy C, Padival S. Impact of a pharmacy resident on a transitions of care rotation for inpatients enrolled in an outpatient parenteral antimicrobial therapy (OPAT) program. Antimicrob Steward Healthc Epidemiol. 2023;3(1):e111. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37502238\/","DOI":"10.1017\/ash.2023.181"},{"key":"2619_CR6","doi-asserted-by":"crossref","unstructured":"Ortonobes S, Mujal-Mart\u00ednez A, de Castro Julve M, Gonz\u00e1lez-S\u00e1nchez A, Jim\u00e9nez-P\u00e9rez R, Hern\u00e1ndez-\u00c1vila M et al. Successful integration of clinical pharmacists in an OPAT program: A real-life multidisciplinary circuit. Antibiotics (Basel). 2022;11(8):1124. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36009993\/","DOI":"10.3390\/antibiotics11081124"},{"key":"2619_CR7","doi-asserted-by":"crossref","unstructured":"Bauer KA, Mangino JE, Paolo-Hohman D, Goff DA. Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: Implementation of a structured approach to improve patient outcomes. Infect Dis Clin Pract (Baltim Md). 2016 [cited 2025 Mar 8];24(6):328\u201331. Available from: https:\/\/ohiostate.elsevierpure.com\/en\/publications\/outpatient-parenteral-antimicrobial-therapy-and-antimicrobial-ste","DOI":"10.1097\/IPC.0000000000000445"},{"key":"2619_CR8","doi-asserted-by":"crossref","unstructured":"Shah A, Petrak R, Fliegelman R, Shrestha N, Allison G, Zurlo J et al. Infectious diseases specialty intervention is associated with better outcomes among privately insured individuals receiving outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2019;68(7):1160\u20135. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30247512\/","DOI":"10.1093\/cid\/ciy674"},{"key":"2619_CR9","unstructured":"Kortajarena X, Goenaga MA, Ibarguren M, Azkune H, Bustinduy MJ, Fuertes A et al. Outpatient parenteral antimicrobial therapy for infective endocarditis in patients over 80 years. Rev Esp Quimioter. 2017;30(4):276\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28585797\/"},{"key":"2619_CR10","doi-asserted-by":"crossref","unstructured":"Mujal A, Sola J, Hernandez M, Villarino M-A, Baylina M, Tajan J et al. Safety and effectiveness of outpatient parenteral antimicrobial therapy in older people. J Antimicrob Chemother. 2016;71(5):1402\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26832749\/","DOI":"10.1093\/jac\/dkv478"},{"key":"2619_CR11","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-L\u00f3pez J, San Jos\u00e9 Laporte A, Pardos-Gea J, Tapia Melench\u00f3n E, Lozano Ort\u00edn E, Barrio Guirado A et al. Safety and efficacy of home intravenous antimicrobial infusion therapy in older patients: a comparative study with younger patients: Intravenous antimicrobial infusion therapy. Int J Clin Pract. 2008;62(8):1188\u201392. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18422588\/","DOI":"10.1111\/j.1742-1241.2008.01747.x"},{"key":"2619_CR12","doi-asserted-by":"crossref","unstructured":"Norris AH, Shrestha NK, Allison GM, Keller SC, Bhavan KP, Zurlo JJ et al. 2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2019;68(1):e1\u201335. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30423035\/","DOI":"10.1093\/cid\/ciy745"},{"key":"2619_CR13","doi-asserted-by":"crossref","unstructured":"Barr DA, Semple L, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) in a teaching hospital-based practice: a retrospective cohort study describing experience and evolution over 10 years. Int J Antimicrob Agents. 2012;39(5):407\u201313. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22445493\/","DOI":"10.1016\/j.ijantimicag.2012.01.016"},{"key":"2619_CR14","doi-asserted-by":"crossref","unstructured":"Muldoon EG, Switkowski K, Tice A, Snydman DR, Allison GM. A national survey of infectious disease practitioners on their use of outpatient parenteral antimicrobial therapy (OPAT). Infect Dis (Lond). 2015;47(1):39\u201345. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25415655\/","DOI":"10.3109\/00365548.2014.967290"},{"key":"2619_CR15","doi-asserted-by":"crossref","unstructured":"Shrestha NK, Shrestha J, Everett A, Carroll D, Gordon SM, Butler RS et al. Vascular access complications during outpatient parenteral antimicrobial therapy at home: a retrospective cohort study. J Antimicrob Chemother. 2016;71(2):506\u201312. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26510718\/","DOI":"10.1093\/jac\/dkv344"},{"key":"2619_CR16","doi-asserted-by":"crossref","unstructured":"Underwood J, Marks M, Collins S, Logan S, Pollara G. Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy. J Antimicrob Chemother. 2019;74(3):787\u201390. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30462237\/","DOI":"10.1093\/jac\/dky474"},{"key":"2619_CR17","doi-asserted-by":"crossref","unstructured":"Barr DA, Semple L, Seaton RA. Self-administration of outpatient parenteral antibiotic therapy and risk of catheter-related adverse events: a retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2012;31(10):2611\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22526869\/","DOI":"10.1007\/s10096-012-1604-z"},{"key":"2619_CR18","doi-asserted-by":"crossref","unstructured":"Wai AO, Frighetto L, Marra CA, Chan E, Jewesson PJ. Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective. Pharmacoeconomics. 2000;18(5):451\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11151398\/","DOI":"10.2165\/00019053-200018050-00004"},{"key":"2619_CR19","doi-asserted-by":"crossref","unstructured":"Durojaiye OC, Bell H, Andrews D, Ntziora F, Cartwright K. Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service. Int J Antimicrob Agents. 2018;51(1):26\u201332. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28673610\/","DOI":"10.1016\/j.ijantimicag.2017.03.016"},{"key":"2619_CR20","doi-asserted-by":"crossref","unstructured":"Karimaghaei S, Rao A, Chijioke J, Finch N, Nigo M. Characteristics, safety and cost-effectiveness analysis of self-administered outpatient parenteral antibiotic therapy via a disposable elastomeric continuous infusion pump at two county hospitals in Houston, Texas, United States. J Clin Pharm Ther. 2022;47(2):211\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34699089\/","DOI":"10.1111\/jcpt.13550"},{"key":"2619_CR21","doi-asserted-by":"crossref","unstructured":"Staples JA, Ho M, Ferris D, Hayek J, Liu G, Tran KC et al. Outpatient versus inpatient intravenous antimicrobial therapy: A population-based observational cohort study of adverse events and costs. Clin Infect Dis. 2022;75(11):1921\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35439822\/","DOI":"10.1093\/cid\/ciac298"},{"key":"2619_CR22","doi-asserted-by":"crossref","unstructured":"Giuliano G, Raffaelli F, Faliero D, Tamburrini E, Tarantino D, Nurchis MC et al. Outpatient parenteral antimicrobial therapy (OPAT) from an emergency model applied during the COVID-19 pandemic to standard of care: Preliminary lessons from our experience. Infect Dis Now. 2023;53(2):104642. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36642101\/","DOI":"10.1016\/j.idnow.2023.01.002"},{"key":"2619_CR23","doi-asserted-by":"publisher","unstructured":"Dimitrova M, Gilchrist M, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses. BMJ Open. 2021;11(9):e049733. Available from: https:\/\/doi.org\/10.1136\/bmjopen-2021-049733","DOI":"10.1136\/bmjopen-2021-049733"},{"key":"2619_CR24","doi-asserted-by":"crossref","unstructured":"Boese CK, Lechler P, Frink M, Hackl M, Eysel P, Ries C. Cost-analysis of inpatient and outpatient parenteral antimicrobial therapy in orthopaedics: A systematic literature review. World J Clin Cases. 2019;7(14):1825\u201336. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31417928\/","DOI":"10.12998\/wjcc.v7.i14.1825"},{"key":"2619_CR25","doi-asserted-by":"crossref","unstructured":"Schmidt-Hellerau K, Baade N, G\u00fcnther M, Scholten N, Lindemann CH, Leisse C et al. Outpatient parenteral antimicrobial therapy (OPAT) in Germany: insights and clinical outcomes from the K-APAT cohort study. Infection. 2024;52(4):1407\u201314. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38478255\/","DOI":"10.1007\/s15010-024-02199-9"},{"key":"2619_CR26","unstructured":"Neubert J, Akarsu Y, M\u00fcller R, von Both U, Stegemann M, Simon A. Ambulante parenterale Antibiotika- therapie in der P\u00e4diatrie: eine wichtige Option f\u00fcr Kinderkliniken in Deutschland. Available from: https:\/\/shop.mhp-verlag.de\/media\/pdf\/e3\/a3\/f2\/hm202409_183_192_Neubert_mit-Literatur.pdf"},{"key":"2619_CR27","doi-asserted-by":"crossref","unstructured":"Saini E, Ali M, Du P, Crook T, Zurlo J. Early infectious disease outpatient follow-up of outpatient parenteral antimicrobial therapy patients reduces 30-day readmission. Clin Infect Dis. 2019;69(5):865\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30721936\/","DOI":"10.1093\/cid\/ciz073"},{"key":"2619_CR28","doi-asserted-by":"crossref","unstructured":"Kaul CM, Haller M, Yang J, Solomon S, Wang Y, Wu R et al. Assessment of risk factors associated with outpatient parenteral antimicrobial therapy (OPAT) complications: A retrospective cohort study. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e183. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36406163\/","DOI":"10.1017\/ash.2022.313"},{"key":"2619_CR29","doi-asserted-by":"crossref","unstructured":"Huck D, Ginsberg JP, Gordon SM, Nowacki AS, Rehm SJ, Shrestha NK. Association of laboratory test result availability and rehospitalizations in an outpatient parenteral antimicrobial therapy programme. J Antimicrob Chemother. 2014;69(1):228\u201333. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23887864\/","DOI":"10.1093\/jac\/dkt303"},{"key":"2619_CR30","doi-asserted-by":"crossref","unstructured":"Keller SC, Ciuffetelli D, Bilker W, Norris A, Timko D, Rosen A et al. The impact of an infectious diseases transition service on the care of outpatients on parenteral antimicrobial therapy. J Pharm Technol. 2013;29(5):205\u201314. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25621307\/","DOI":"10.1177\/8755122513500922"},{"key":"2619_CR31","doi-asserted-by":"crossref","unstructured":"Sharma R, Loomis W, Brown RB. Impact of mandatory inpatient infectious disease consultation on outpatient parenteral antibiotic therapy. Am J Med Sci. 2005;330(2):60\u20134. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16103785\/","DOI":"10.1097\/00000441-200508000-00002"},{"key":"2619_CR32","doi-asserted-by":"crossref","unstructured":"Conant MM, Erdman SM, Osterholzer D. Mandatory infectious diseases approval of outpatient parenteral antimicrobial therapy (OPAT): clinical and economic outcomes of averted cases. J Antimicrob Chemother. 2014;69(6):1695\u2013700. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24532684\/","DOI":"10.1093\/jac\/dku015"},{"key":"2619_CR33","doi-asserted-by":"crossref","unstructured":"Heintz BH, Halilovic J, Christensen CL. Impact of a multidisciplinary team review of potential outpatient parenteral antimicrobial therapy prior to discharge from an academic medical center. Ann Pharmacother. 2011;45(11):1329\u201337. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21990938\/","DOI":"10.1345\/aph.1Q240"},{"key":"2619_CR34","doi-asserted-by":"publisher","unstructured":"Vehreschild MJGT, F\u00e4tkenheuer G, Sander LE, L\u00fcbbert C, Rieg S, Ertl G et al. Infectious diseases - a new specialty for postgraduate training in Germany. Dtsch Med Wochenschr. 2024 [cited 2025 Jul 18];149(9):533\u20136. Available from: https:\/\/doi.org\/10.1055\/a-2258-7265","DOI":"10.1055\/a-2258-7265"},{"key":"2619_CR35","unstructured":"de With K, Wilke K, Kern WV, Strau\u00df R, Kramme E, Friedrichs A et al. S3- Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. Available from: https:\/\/register.awmf.org\/assets\/guidelines\/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02-abgelaufen.pdf"},{"key":"2619_CR36","volume-title":": a practical guide","author":"Antimicrobial stewardship interventions","year":"2021","unstructured":"Antimicrobial stewardship interventions.: a practical guide. Copenhagen: WHO Regional Office for Europe; 2021. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"2619_CR37","doi-asserted-by":"publisher","unstructured":"Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-77. Available from: https:\/\/doi.org\/10.1093\/cid\/ciw118","DOI":"10.1093\/cid\/ciw118"},{"key":"2619_CR38","unstructured":"Start smart then focus: antimicrobial stewardship toolkit for inpatient care settings. Gov.uk. [cited 2025 Jul 11]. Available from: https:\/\/www.gov.uk\/government\/publications\/antimicrobial-stewardship-start-smart-then-focus\/start-smart-then-focus-antimicrobial-stewardship-toolkit-for-inpatient-care-settings"},{"key":"2619_CR39","doi-asserted-by":"publisher","unstructured":"Schuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWTC, Overdiek HWPM et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):847\u201356. Available from: https:\/\/doi.org\/10.1016\/S1473-3099(16)00065-7","DOI":"10.1016\/S1473-3099(16)00065-7"},{"key":"2619_CR40","doi-asserted-by":"publisher","unstructured":"Mahoney MV, Ryan KL, Alexander BT. Evaluation of OPAT in the age of antimicrobial stewardship. Curr Treat Options Infect Dis. 2020 [cited 2025 Jul 18];12(2):158\u201377. Available from: https:\/\/doi.org\/10.1007\/s40506-020-00217-6","DOI":"10.1007\/s40506-020-00217-6"},{"key":"2619_CR41","doi-asserted-by":"publisher","unstructured":"Wald-Dickler N, Holtom PD, Phillips MC, Centor RM, Lee RA, Baden R et al. Oral is the new IV. Challenging decades of blood and bone infection dogma: a systematic review. Am J Med. 2022;135(3):369\u2013379.e1. Available from: https:\/\/doi.org\/10.1016\/j.amjmed.2021.10.007","DOI":"10.1016\/j.amjmed.2021.10.007"},{"key":"2619_CR42","doi-asserted-by":"crossref","unstructured":"Allwood MC, Stonkute D, Wallace A, Wilkinson A-S, Hills T, Jamieson C et al. Assessment of the stability of citrate-buffered flucloxacillin for injection when stored in two commercially available ambulatory elastomeric devices: INfusor LV (Baxter) and Accufuser (Woo Young Medical): a study compliant with the NHS Yellow Cover Document (YCD) requirements. Eur J Hosp Pharm Sci Pract. 2020;27(2):90\u20134. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32153771\/","DOI":"10.1136\/ejhpharm-2018-001515"},{"key":"2619_CR43","doi-asserted-by":"crossref","unstructured":"Jamieson C, Allwood MC, Stonkute D, Wallace A, Wilkinson A-S, Hills T et al. Investigation of meropenem stability after reconstitution: the influence of buffering and challenges to meet the NHS Yellow Cover Document compliance for continuous infusions in an outpatient setting. Eur J Hosp Pharm Sci Pract. 2020 [cited 2025 Mar 8];27(e1):e53\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32296506\/","DOI":"10.1136\/ejhpharm-2018-001699"},{"key":"2619_CR44","doi-asserted-by":"crossref","unstructured":"Jamieson C, Ozolina L, Seaton RA, Gilchrist M, Hills T, Drummond F et al. Assessment of the stability of citrate-buffered piperacillin\/tazobactam for continuous infusion when stored in two commercially available elastomeric devices for outpatient parenteral antimicrobial chemotherapy: a study compliant with the NHS Yellow Cover Document requirements. Eur J Hosp Pharm Sci Pract. 2022;29(4):212\u20136. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32978220\/","DOI":"10.1136\/ejhpharm-2020-002340"},{"key":"2619_CR45","doi-asserted-by":"crossref","unstructured":"Patel RP, Jacob J, Sedeeq M, Ming LC, Wanandy T, Zaidi STR et al. Stability of cefazolin in polyisoprene elastomeric infusion devices. Clin Ther. 2018;40(4):664\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29496321\/","DOI":"10.1016\/j.clinthera.2018.02.009"},{"key":"2619_CR46","doi-asserted-by":"crossref","unstructured":"Jenkins A, Hills T, Santillo M, Gilchrist M, Drug Stability Working Group of the BSAC UK OPAT Initiative. Extended stability of antimicrobial agents in administration devices. J Antimicrob Chemother. 2017;72(4):1217\u201320. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28073966\/","DOI":"10.1093\/jac\/dkw556"},{"key":"2619_CR47","doi-asserted-by":"crossref","unstructured":"Jenkins A, Jamieson C, Santillo M. Systematic review of room temperature stability of key beta-lactam antibiotics for extended infusions in inpatient settings. Eur J Hosp Pharm Sci Pract. 2023;31(1):2\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37848286\/","DOI":"10.1136\/ejhpharm-2023-003855"},{"key":"2619_CR48","doi-asserted-by":"crossref","unstructured":"Jenkins A, Shanu S, Jamieson C, Santillo M. Systematic review of the stability of antimicrobial agents in elastomeric devices for outpatient parenteral antimicrobial therapy services based on NHS Yellow Cover Document standards. Eur J Hosp Pharm Sci Pract. 2022;29(6):304\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33990388\/","DOI":"10.1136\/ejhpharm-2021-002729"},{"key":"2619_CR49","doi-asserted-by":"crossref","unstructured":"Jenkins A, Shanu S, Jamieson C, Santillo M. Widening the net: a literature review of antimicrobial agents with potential suitability for outpatient parenteral antimicrobial therapy services-the importance of storage and stability. Eur J Hosp Pharm Sci Pract. 2023;30(2):64\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34862256\/","DOI":"10.1136\/ejhpharm-2021-002937"},{"key":"2619_CR50","doi-asserted-by":"crossref","unstructured":"Perks SJ, Lanskey C, Robinson N, Pain T, Franklin R. Systematic review of stability data pertaining to selected antibiotics used for extended infusions in outpatient parenteral antimicrobial therapy (OPAT) at standard room temperature and in warmer climates. Eur J Hosp Pharm Sci Pract. 2020;27(2):65\u201372. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32133131\/","DOI":"10.1136\/ejhpharm-2019-001875"},{"key":"2619_CR51","doi-asserted-by":"crossref","unstructured":"Foy F, Luna G, Martinez J, Nizich Z, Seet J, Lie K et al. An investigation of the stability of meropenem in elastomeric infusion devices. Drug Des Devel Ther. 2019;13:2655\u201365. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31447546\/","DOI":"10.2147\/DDDT.S212052"},{"key":"2619_CR52","doi-asserted-by":"crossref","unstructured":"de Souza Barbosa F, Capra Pezzi L, Tsao M, Franco de Oliveira T, Manoela Dias Macedo S, Schapoval ES et al. E,. Stability and degradation products of imipenem applying high-resolution mass spectrometry: An analytical study focused on solutions for infusion. Biomed Chromatogr. 2019;33(4):e4471. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30549056\/","DOI":"10.1002\/bmc.4471"},{"key":"2619_CR53","doi-asserted-by":"crossref","unstructured":"Diamantis S, Dawudi Y, Cassard B, Longuet P, Lesprit P, Gauzit R. Antibioth\u00e9rapie intra-veineuse \u00e0 domicile et bon usage des diffuseurs \/ Home intravenous antibiotherapy and the proper use of elastomeric pumps. Infect Dis Now. 2021;51(1):39\u201349. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33576336\/","DOI":"10.1016\/j.medmal.2020.10.019"},{"key":"2619_CR54","unstructured":"Maher M, Jensen KJ, Lee D, Nix DE. Stability of ampicillin in normal saline and buffered normal saline. Int J Pharm Compd. 2016;20(4):338\u201342. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28333679\/"},{"key":"2619_CR55","doi-asserted-by":"crossref","unstructured":"Nakamura T, Enoki Y, Uno S, Uwamino Y, Iketani O, Hasegawa N et al. Stability of benzylpenicillin potassium and ampicillin in an elastomeric infusion pump. J Infect Chemother. 2018;24(10):856\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29705391\/","DOI":"10.1016\/j.jiac.2018.04.003"},{"key":"2619_CR56","unstructured":"Gesetz \u00fcber den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG) \u00a7 13 Herstellungserlaubnis."},{"key":"2619_CR57","doi-asserted-by":"crossref","unstructured":"Walker SE, Iazzetta J, Law S, Biniecki K. Stability of commonly used antibiotic solutions in an elastomeric infusion device. Can J Hosp Pharm. 2010;63(3):212\u201324. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22478981\/","DOI":"10.4212\/cjhp.v63i3.917"},{"key":"2619_CR58","unstructured":"Guidelines of 19. March 2015 on principles of good distribution practice of active substances for medicinal products for human use. EudraLex. 2015;4(C 95\/01)."},{"key":"2619_CR59","doi-asserted-by":"crossref","unstructured":"Moureau N, Poole S, Murdock MA, Gray SM, Semba CP. Central venous catheters in home infusion care: outcomes analysis in 50,470 patients. J Vasc Interv Radiol. 2002;13(10):1009\u201316. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12397122\/","DOI":"10.1016\/S1051-0443(07)61865-X"},{"key":"2619_CR60","doi-asserted-by":"crossref","unstructured":"Scholten N, Leisse C, Brandes V, Oberr\u00f6hrmann C, Ihle P, Peter S et al. Outpatient parenteral antimicrobial therapy in Germany: a prospective cohort study protocol. BMJ Open. 2022;12(11):e061417. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36375971\/","DOI":"10.1136\/bmjopen-2022-061417"},{"key":"2619_CR61","doi-asserted-by":"publisher","unstructured":"Bentridi A, Giroux M-F, Soulez G, Bouchard L, Perreault P, Chouinard A et al. Midline venous catheter vs peripherally inserted central catheter for intravenous therapy: A randomized clinical trial: A randomized clinical trial. JAMA Netw Open. 2025 [cited 2025 Jul 25];8(3):e251258. Available from: https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.1258","DOI":"10.1001\/jamanetworkopen.2025.1258"},{"key":"2619_CR62","doi-asserted-by":"crossref","unstructured":"Keller SC, Salinas A, Gurses AP, Levering M, Hohl D, Hirsch D et al. Implementing a toolkit to improve the education of patients on home-based outpatient parenteral antimicrobial therapy (OPAT). Jt Comm J Qual Patient Saf. 2022;48(9):468\u201374. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35850954\/","DOI":"10.1016\/j.jcjq.2022.05.008"},{"key":"2619_CR63","doi-asserted-by":"crossref","unstructured":"Baecker H, Gessmann J, Hanusrichter Y, Zahn PK, Schildhauer TA, Frieler S. Outpatient parenteral antibiotic therapy (OPAT) with peripherally inserted central catheter in patients with periprosthetic joint infection. Z Orthop Unfall. 2019;157(5):510\u20134. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31387123\/","DOI":"10.1055\/a-0830-4776"},{"key":"2619_CR64","doi-asserted-by":"crossref","unstructured":"Shrestha NK, Kim SL, Rehm SJ, Everett A, Gordon SM. Emergency department visits during outpatient parenteral antimicrobial therapy: a retrospective cohort study. J Antimicrob Chemother. 2018;73(7):1972\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29684172\/","DOI":"10.1093\/jac\/dky133"},{"key":"2619_CR65","doi-asserted-by":"crossref","unstructured":"Durojaiye OC, Cole J, Kritsotakis EI. Risk of venous thromboembolism in outpatient parenteral antimicrobial therapy (OPAT): A systematic review and meta-analysis. Int J Antimicrob Agents. 2023;62(3):106911. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37422098\/","DOI":"10.1016\/j.ijantimicag.2023.106911"},{"key":"2619_CR66","doi-asserted-by":"crossref","unstructured":"Citla Sridhar D, Abou-Ismail MY, Ahuja SP. Central venous catheter-related thrombosis in children and adults. Thromb Res. 2020;187:103\u201312. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31981840\/","DOI":"10.1016\/j.thromres.2020.01.017"},{"key":"2619_CR67","doi-asserted-by":"crossref","unstructured":"Chary A, Tice AD, Martinelli LP, Liedtke LA, Plantenga MS, Strausbaugh LJ et al. Experience of infectious diseases consultants with outpatient parenteral antimicrobial therapy: results of an emerging infections network survey. Clin Infect Dis. 2006;43(10):1290\u20135. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17051494\/","DOI":"10.1086\/508456"},{"key":"2619_CR68","doi-asserted-by":"crossref","unstructured":"Corwin P, Toop L, McGeoch G, Than M, Wynn-Thomas S, Wells JE et al. Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. BMJ. 2005;330(7483):129. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15604157\/","DOI":"10.1136\/bmj.38309.447975.EB"},{"key":"2619_CR69","doi-asserted-by":"crossref","unstructured":"Briggs S, Smith S, Ritchie S, Fitzharris P, Ellis-Pegler R. Late-onset bolus intravenous beta-lactam antibiotic adverse reaction: short-lived symptoms during drug administration and associated laboratory abnormalities. Scand J Infect Dis. 2014;46(1):14\u201320. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24215337\/","DOI":"10.3109\/00365548.2013.849815"},{"key":"2619_CR70","doi-asserted-by":"crossref","unstructured":"Blumenthal KG, Youngster I, Rabideau DJ, Parker RA, Manning KS, Walensky RP et al. Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. J Allergy Clin Immunol. 2015 [cited 2025 Mar 9];136(5):1288-94.e1. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25981739\/","DOI":"10.1016\/j.jaci.2015.04.005"},{"key":"2619_CR71","doi-asserted-by":"publisher","unstructured":"Sunagawa SW, Arduser S, Miller MM, Lyden E, LeMaster M, Cortes-Penfield N et al. Serious adverse events and laboratory monitoring regimens for outpatient parenteral antimicrobial therapy with cefazolin and ceftriaxone. Open Forum Infect Dis. 2023 [cited 2025 Jul 11];10(12):ofad606. Available from: https:\/\/doi.org\/10.1093\/ofid\/ofad606","DOI":"10.1093\/ofid\/ofad606"},{"key":"2619_CR72","doi-asserted-by":"crossref","unstructured":"Aberdein J, Chapman ALN. Clostridium difficile infection following outpatient parenteral antimicrobial therapy. J Hosp Infect. 2015;90(2):171\u20132. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25922336\/","DOI":"10.1016\/j.jhin.2015.02.010"},{"key":"2619_CR73","doi-asserted-by":"crossref","unstructured":"Petrak RM, Skorodin NC, Fliegelman RM, Hines DW, Chundi VV, Harting BP. Value and clinical impact of an infectious disease-supervised outpatient parenteral antibiotic therapy program. Open Forum Infect Dis. 2016;3(4):ofw193. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27807591\/","DOI":"10.1093\/ofid\/ofw193"},{"key":"2619_CR74","doi-asserted-by":"publisher","unstructured":"Durojaiye OC, Jibril I, Kritsotakis EI. Effectiveness of telemedicine in outpatient parenteral antimicrobial therapy (Tele-OPAT): A systematic review. J Telemed Telecare. 2024;30(8):1230\u20137. Available from: https:\/\/doi.org\/10.1177\/1357633X221131842","DOI":"10.1177\/1357633X221131842"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02619-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02619-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02619-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:53:12Z","timestamp":1781610792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02619-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2619"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02619-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6895627\/v1","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"14 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.L. has received honoraria for lectures at educational events or for consultancy services from MSD, Novartis, Gilead, GSK, Janssen, Pfizer, Baxter and ViiV. The author has also received research funding from the German Federal Joint Committee (G-BA) for an OPAT study (funding code FKZ: 01VSF18036). The author declares no conflicts of interest related to this publication. All other authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}